Communications Biology (Oct 2024)

Hippo pathway in cancer cells induces NCAM1+αSMA+ fibroblasts to modulate tumor microenvironment

  • Chanida Thinyakul,
  • Yasuhisa Sakamoto,
  • Mayuko Shimoda,
  • Yanliang Liu,
  • Suyanee Thongchot,
  • Omnia Reda,
  • Akihiro Nita,
  • Romgase Sakamula,
  • Somponnat Sampattavanich,
  • Ayato Maeda,
  • Paweenapon Chunthaboon,
  • David Nduru,
  • Mayumi Niimura,
  • Yohei Kanamori,
  • Peti Thuwajit,
  • Keiichi I. Nakayama,
  • Kun-Liang Guan,
  • Yorifumi Satou,
  • Chanitra Thuwajit,
  • Toshiro Moroishi

DOI
https://doi.org/10.1038/s42003-024-07041-4
Journal volume & issue
Vol. 7, no. 1
pp. 1 – 15

Abstract

Read online

Abstract Cancer cells adeptly manipulate the tumor microenvironment (TME) to evade host antitumor immunity. However, the role of cancer cell-intrinsic signaling in shaping the immunosuppressive TME remains unclear. Here, we found that the Hippo pathway in cancer cells orchestrates the TME by influencing the composition of cancer-associated fibroblasts (CAFs). In a 4T1 mouse breast cancer model, Hippo pathway kinases, large tumor suppressor 1 and 2 (LATS1/2), promoted the formation of neural cell adhesion molecule 1 (NCAM1)+alpha-smooth muscle actin (αSMA)+ CAFs expressing the transforming growth factor-β, which is associated with T cell inactivation and dysfunction. Depletion of LATS1/2 in cancer cells resulted in a less immunosuppressive TME, indicated by the reduced proportions of NCAM1+αSMA+ CAFs and dysfunctional T cells. Notably, similar Hippo pathway-induced NCAM1+αSMA+ CAFs were observed in human breast cancer, highlighting the potential of TME-manipulating strategies to reduce immunosuppression in cancer immunotherapy.